MA55140A - SAFE AND EFFECTIVE METHOD OF TREATING ULTRACOLITIS WITH AN ANTI-IL12/IL23 ANTIBODY - Google Patents
SAFE AND EFFECTIVE METHOD OF TREATING ULTRACOLITIS WITH AN ANTI-IL12/IL23 ANTIBODYInfo
- Publication number
- MA55140A MA55140A MA055140A MA55140A MA55140A MA 55140 A MA55140 A MA 55140A MA 055140 A MA055140 A MA 055140A MA 55140 A MA55140 A MA 55140A MA 55140 A MA55140 A MA 55140A
- Authority
- MA
- Morocco
- Prior art keywords
- ultracolitis
- antibody
- safe
- treating
- effective method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862735501P | 2018-09-24 | 2018-09-24 | |
PCT/IB2019/058098 WO2020065532A1 (en) | 2018-09-24 | 2019-09-24 | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
MA55140A true MA55140A (en) | 2021-09-29 |
MA55140B1 MA55140B1 (en) | 2023-09-27 |
Family
ID=88507038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA55140A MA55140B1 (en) | 2018-09-24 | 2019-09-24 | SAFE AND EFFECTIVE METHOD OF TREATMENT OF Ulcerative Colitis WITH AN ANTI-IL12/IL23 ANTIBODY |
Country Status (1)
Country | Link |
---|---|
MA (1) | MA55140B1 (en) |
-
2019
- 2019-09-24 MA MA55140A patent/MA55140B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA55140B1 (en) | 2023-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50666A (en) | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12 / IL23 ANTIBODY | |
MA50580A (en) | SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIC ARTHRITIS WITH A SPECIFIC ANTIBODY ANTI-IL23 | |
MA52962A (en) | CANCER TREATMENT METHODS WITH BISPECIFIC ANTI-CD3XMUC16 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | |
IL281642A (en) | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody | |
MA51899A (en) | INHIBITORS OF BTK AND THEIR MUTANTS | |
DK3411151T3 (en) | Microfluidic assay system and method of performing an assay | |
AR099465A1 (en) | ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE | |
DK3390442T3 (en) | Anti-C5 antibodies and method of use thereof | |
DK3618928T3 (en) | Anti-Sortilin antibodies and methods of use thereof | |
EA201501139A1 (en) | METHOD FOR DETECTING EXPLOSIVE AND OTHER TARGET SUBSTANCES | |
MA43867A (en) | MIXING AND PROCESSING APPARATUS AND METHOD | |
MA52190A (en) | ANTI-TREM-1 ANTIBODIES AND ASSOCIATED USES | |
FR3026745B1 (en) | METHOD OF ANALYSIS AND AUTOMATED INTERPRETATION OF ANTIBIOGRAM | |
MA56124A (en) | SAFE AND EFFECTIVE METHOD OF TREATING PSORIATIC ARTHRITIS USING AN ANTI-IL23 SPECIFIC ANTIBODY | |
MA41462A (en) | METHOD OF TREATMENT OF DISEASES | |
DK3455825T3 (en) | APPARATUS AND METHOD OF BRIDGE ANALYSIS | |
MA45997A (en) | METHODS OF TREATING CROHN'S DISEASE WITH AN ANTI-NKG2D ANTIBODY | |
DK3231405T3 (en) | Method of predicting secretions and their arrangement | |
IT201700045342A1 (en) | Method and equipment of non-destructive investigation on a trunk to determine non-blued internal areas | |
MA54562A (en) | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY | |
EP3793521A4 (en) | Safe and effective method of treating lupus with anti-il12/il23 antibody | |
MA55140A (en) | SAFE AND EFFECTIVE METHOD OF TREATING ULTRACOLITIS WITH AN ANTI-IL12/IL23 ANTIBODY | |
FI20175649A (en) | A method of operating a combustion engine and a combustion engine | |
IL286387A (en) | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody | |
MA55149A (en) | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY |